Description
Springer mTOR Inhibition for Cancer Therapy Past Present and Future 1st Editon 2015 Hardbound by Monica Mita, Alain Mita, Eric K. Rowinsky
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. Forward.- Past.- mTOR inhibitors: a little bit of history.- Present.- The mTOR pathway .- The evolving role of mTOR inhibitors in renal cell carcinoma.- The role of mTOR inhibitors in breast cancer.- The role of mTOR inhibitors in neuroendocrine tumors.- New indications of mTOR inhibitors in rare tumors.- The role of mTOR inhibitors in the treatment of hematological malignancies.- The clinical pharmacology and toxicity profile of rapalogs.- Resistance to mTOR inhibitors.- Rational combinations of mTOR inhibitors as anticancer strategies.- Future.- Predictive biomarkers of response to mTOR inhibitors.- The potential future indication of rapamycin analogs for the treatment of other solid tumors.- mTOR inhibition beyond rapalogs.- mTOR, aging and cancer: the missing link?.- New study design for mTOR inhibitors and other biological agents.- Future directions for the development of mTOR inhibitors.